Kura Oncology, Inc. Appoints James Basta as Chief Legal Officer, Corporate Secretary and Chief Compliance Officer
November 04, 2019 at 07:30 am EST
Share
Kura Oncology, Inc. announced the appointment of James Basta as Chief Legal Officer and Corporate Secretary. Mr. Basta will also serve as the company’s Chief Compliance Officer. Mr. Basta joins Kura with more than 20 years of combined in-house corporate and law firm experience. Most recently, he served as Senior Vice President, Chief Corporation Counsel at Biogen, where he managed the legal representation for Biogen’s securities filings, board of directors, business development, finance and tax, corporate affairs, employment and information technology. Prior to joining Biogen in 2006, he was Partner, Corporate and Securities Practice Group at Baker & McKenzie. Mr. Basta earned his J.D. from Northwestern University School of Law and his B.A. in Economics from Northwestern University.
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.